好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Characterizing Pathological Laughing and Crying in Progressive Supranuclear Palsy
Aging, Dementia, and Behavioral Neurology
P7 - Poster Session 7 (8:00 AM-9:00 AM)
12-005

To examine the prevalence and characteristics of pathological laughing and crying in progressive supranuclear palsy (PSP).

Pseudobulbar affect (PBA), or pathological laughing and crying, is a poorly understood clinical phenomenon that lacks standardized diagnostic criteria. Prior studies have suggested that PBA is common in certain neurodegenerative disorders, such as PSP, but large cohort studies on the prevalence and features of PBA in PSP are lacking.

We conducted a retrospective chart review to evaluate laughing and crying in 210 individuals with PSP who presented to the University of California, San Francisco Memory and Aging Center between 1998 and 2023. Using objective criteria, two raters recorded whether each patient exhibited laughing and crying behaviors that were deemed to be frequent, uncontrollable, or inappropriate. The ratings were then used to classify individuals as having probable or possible PBA. We next compared these classifications with the clinician’s diagnosis of PBA at the time of the evaluation.

The mean age of the patients at the time of the clinical evaluation was 69.2 ± 7.3 years, and the sample consisted of 54% males. Our chart review identified PBA in 53 (25%) of the individuals with PSP: 27 (13%) with probable PBA and 26 (12%) with possible PBA. The clinicians who conducted the evaluations, in contrast, diagnosed PBA in only 30 individuals (14%) in the cohort. There was agreement between the chart review classifications and the clinician ratings of PBA in 21 (78%) of individuals with probable PBA in the chart review and in 7 (27%) of the individuals with possible PBA in the chart review.

Our results suggest that pathological laughing and crying is common in PSP.  A better understanding of the clinical phenomenology of PBA will be important for clinicians to evaluate this symptom.

Authors/Disclosures
Kaancan Deniz, MD (UCSF Department of Neurology)
PRESENTER
Dr. Deniz has nothing to disclose.
Velda Han, PhD Dr. Han has nothing to disclose.
Zachary Miller, MD (UCSF Memory and Aging Center) Dr. Miller has nothing to disclose.
Maria Luisa Gorno Tempini, MD, PhD (UCSF Memory and Aging Center) The institution of Dr. Gorno Tempini has received research support from the NIH.
Howard J. Rosen, MD (UCSF) Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly . Dr. Rosen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alector. The institution of Dr. Rosen has received research support from NIH. The institution of Dr. Rosen has received research support from State of CA. Dr. Rosen has a non-compensated relationship as a Consultant with Prevail Therapeutics that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a consultant with Alchemab that is relevant to AAN interests or activities.
Adam L. Boxer, MD, PhD (University of California, San Francisco) An immediate family member of Dr. Boxer has received personal compensation for serving as an employee of Kaiser Permanente. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ono. Dr. Boxer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Oscotec. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Boxer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Arrowhead. Dr. Boxer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine Biosciences. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Switch. Dr. Boxer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Arvinas. Dr. Boxer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alector. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Boxer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Transposon. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen . Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Boxer has stock in Alector. Dr. Boxer has stock in Arvinas. Dr. Boxer has stock in Neurovanda. The institution of Dr. Boxer has received research support from Biogen. The institution of Dr. Boxer has received research support from Eisai. The institution of Dr. Boxer has received research support from Regeneron. The institution of Dr. Boxer has received research support from NIH. The institution of Dr. Boxer has received research support from Bluefield Project-5. Dr. Boxer has received research support from Rainwater Charitable Foundation. Dr. Boxer has received research support from GHR Foundation. Dr. Boxer has received intellectual property interests from a discovery or technology relating to health care.
Bruce L. Miller, MD, FAAN (University of California, San Francisco) Dr. Miller has nothing to disclose.
William W. Seeley, MD Dr. Seeley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG Council. Dr. Seeley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint Global Consulting. Dr. Seeley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BridgeBio. Dr. Seeley has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Seeley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lyterian Therapeutics. The institution of Dr. Seeley has received research support from NIH. The institution of Dr. Seeley has received research support from Rainwater Charitable Foundation. The institution of Dr. Seeley has received research support from Bluefield Project to Cure FTD. The institution of Dr. Seeley has received research support from Chan-Zuckerberg Initiative.
Virginia Sturm, PhD Dr. Sturm has nothing to disclose.